BridgeBio Pharma stock is trading -17.97% below its average target price of $83.56 after marking a 6.1% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $63.0 to $110.0 per share.
The stock has an unusually large proportion of its shares sold short at 17.0%, and a short ratio of 7.76. The company's insiders own 4.74% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.9% of BridgeBio Pharma's shares being owned by this investor type.
Institutions Invested in BridgeBio Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Vanguard Group Inc | 9% | 16,832,059 | $1,153,697,976 |
| 2025-09-30 | Viking Global Investors, L.P. | 8% | 15,977,849 | $1,095,148,969 |
| 2025-09-30 | Blackrock Inc. | 7% | 14,411,203 | $987,768,385 |
| 2025-09-30 | Kohlberg Kravis Roberts & Co. L.P. | 7% | 13,260,971 | $908,929,526 |
| 2025-09-30 | Janus Henderson Group PLC | 5% | 8,741,079 | $599,128,434 |
| 2025-09-30 | Farallon Capital Management LLC | 4% | 8,192,000 | $561,493,625 |
| 2025-09-30 | Aisling Capital Management LP | 3% | 6,089,611 | $417,392,304 |
| 2025-09-30 | State Street Corporation | 3% | 5,606,340 | $384,268,087 |
| 2025-09-30 | Invesco Ltd. | 2% | 3,928,657 | $269,276,838 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 3,909,941 | $267,994,011 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on BridgeBio Pharma.
